Biphenyl compounds useful as muscarinic receptor antagonists
The invention provides compounds of formula I: wherein a, b, c, d, n, R 1 , R 2 , R 3 , R 6 , R 7 , W, and A are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
1. A compound of formula I:
wherein:
a is 0 or 1;
R 1 is halo;
b is 0 or 1;
R 2 is halo;
W represents O;
c is 0;
A is selected from:
where m is 0 or 1; s is 0, 1 or 2; t is 0, 1 or 2; R 4 is hydrogen or (1-4C)alkyl; and Ar 1 represents a phenylene group substituted with (R 5 ) q where q is 0 or an integer from 1 to 4 and each R 5 is independently selected from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy;
n is 1 or 2;
d is 0;
R 7 is selected from hydrogen, —OH, -(1-4C)alkyleneOH, —NR 7a R 7b , —C(O)NR 7c R 7d , and —CH 2 C(O)NR 7c R 7d , where R 7a , R 7b , and R 7c are independently selected from hydrogen, (1-4C)alkyl, hydroxy, (1-4C)alkoxy, (1-4C)alkyleneOR 7e , (3-6C)cycloalkyl, phenyl optionally substituted with hydroxy, (1-4C)alkyleneC(O)NR 7f R 7G ; and R 7d is selected from hydroxy, (1-4C)alkoxy, (1-4C)alkyleneOR 7h , (3-6C)cycloalkyl, phenyl optionally substituted with hydroxy, and (1-4C)alkyleneC(O)NR 7i R 7j ; where said (3-6C)cyeloalkyl is unsubstituted or substituted with 1 or 2 (1-6C)alkyl or —NR 7k R 7l groups, and where each of R 7e , R 7f , R 7g , R 7h , R 7i , R 7j , R 7k , and R 7l is independently hydrogen or (1-4C)alkyl; or R 7c is taken together with R 7d to form a 3-7 membered ring, optionally substituted with hydroxyl;
wherein each alkyl and alkoxy group in R 7a-l is optionally substituted with 1 to 5 fluoro substituents;
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. The compound of claim 1 , wherein a and b each represent 0.
3. The compound of claim 1 , wherein m is 0.
4. The compound of claim 1 , wherein R 4 is hydrogen or methyl.
5. The compound of claim 1 , wherein A is:
where m is 0; s is 0 or 2; t is 1; R 4 is hydrogen or methyl; and Ar l represents a phenylene group substituted with (R 5 ) q where q is 0 or q is 1 and R 5 is halo.
6. The compound of claim 1 , wherein R 7 is hydrogen.
7. The compound of claim 1 , wherein R 7 is —OH.
8. The compound of claim 1 , wherein R 7 is —CH 2 OH or —(CH 2 ) 2 OH.
9. The compound of claim 1 , wherein R 7 is —C(O)NR 7C R 7d , where R 7c is hydrogen, and R 7d is selected from —(CH 2 ) 2 OH, —(CH 2 ) 2 OCH 3 , cyclopropyl, cyclopentyl, phenyl optionally substituted with hydroxy, and —(CH 2 )C(O)NH 2 .
10. The compound of claim 1 , wherein R 7 is —C(O)NR 7c R 7d , where R 7c is taken together with R 7d to form pyrrolidine, piperidine, 3-hydroxypiperidine, or 4-hydroxypiperidine.
11. The compound of claim 1 , selected from:
biphenyl-2-ylcarbamic acid 1-[2-( {4-[4-(2-hydroxyethylcarbamoyl)piperidin-1-ylmethyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-( {4-[4-(2-methoxyethylcarbamoyl)piperidin-1-ylmethyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-cyclopropylcarbamoylpiperidin-1-ylmethyl)benzoyl]methylamino }ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-cyclopentylcarbamoylpiperidin-1-ylmethyl) benzoyl]methylamino}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-( {4-[4-(4-hydroxybenzylcarbamoyl)piperidin-1-ylmethyl]benzoyl}methylmino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-benzylcarbamoylpiperidin-1-ylmethyl) benzoyl]methylamino}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-({4-[4-(carbamoylmethylcarbamoyl)piperidin-1-ylmethyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-( {4-[4-(4-hydroxypiperidine-1-carbonyl)piperidin-1-ylmethyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-( {4-[4-(3-hydroxypiperidine-1-carbonyl)piperidin-1-ylmethyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-(methyl-{4-[4-(pyrrolidine-1-carbonyl)piperidin-1-ylmethyl]benzoyl}amino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-(methyl-{4-[4-(piperidine-1-carbonyl)piperidin-1-ylmethyl]benzoyl}amino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-hydroxymethylpiperidin-1-ylmethyl) benzoyl]methylamino}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-hydroxypiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{[2-fluoro-4-(4-hydroxypiperidin-1-ylmethyl) benzoyl]methylamino }ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-({3-[4-(4-hydroxypiperidin-1-ylmethyl)phenyl]propionyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-({3-[4-(3-hydroxypiperidin-1-ylmethyl)phenyl]propionyl}methylamino)ethyl]piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-{2-[3-(4-piperidin-1-ylmethylphenyl) propionylamino]ethyl}piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{3- [4-(4-hydroxypiperidin-1-ylmethyl)phenyl]propionylamino }ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{3- [4-(3-hydroxypiperidin-1-ylmethyl)phenyl]propionylamino }ethyl)piperidin-4-yl ester; and
biphenyl-2-ylcarbamic acid 1-{2-[methyl-(4-pyrrolidin-1-ylmethyl-benzoyl) amino]ethyl}piperidin-4-yl ester;
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 .